Last reviewed · How we verify
noradrenaline and vascular filling
noradrenaline and vascular filling is a Sympathomimetic Small molecule drug developed by Centre Hospitalier Universitaire, Amiens. It is currently in Phase 3 development for Hypotension, Anaphylactic shock.
Noradrenaline increases vascular tone and cardiac contractility by stimulating alpha-1 adrenergic receptors.
Noradrenaline increases vascular tone and cardiac contractility by stimulating alpha-1 adrenergic receptors. Used for Hypotension, Anaphylactic shock.
At a glance
| Generic name | noradrenaline and vascular filling |
|---|---|
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Drug class | Sympathomimetic |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This results in increased blood pressure and cardiac output. Noradrenaline also has a positive inotropic effect, increasing the force of cardiac contractions.
Approved indications
- Hypotension
- Anaphylactic shock
Common side effects
- Tachycardia
- Hypertension
- Headache
- Nausea
- Vomiting
- Dizziness
- Palpitations
- Tremors
- Angina
- Chest pain
Key clinical trials
- Decrease of Post-operative Complications by SCVO2 Monitoring an Optimisation of Cardiac Flow (NA)
- Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?
- Individualized Hemodynamic Optimization by Indirect Measurement of the Respiratory Quotient in Major Surgery: Prospective Randomized Multicentre Open-Label Study (OPHIQUE) Individualized Optimization by Indirect Measurement of the Respiratory Quotient (NA)
- Lung Ultrasound-guided Hemodynamic Optimization (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- noradrenaline and vascular filling CI brief — competitive landscape report
- noradrenaline and vascular filling updates RSS · CI watch RSS
- Centre Hospitalier Universitaire, Amiens portfolio CI
Frequently asked questions about noradrenaline and vascular filling
What is noradrenaline and vascular filling?
How does noradrenaline and vascular filling work?
What is noradrenaline and vascular filling used for?
Who makes noradrenaline and vascular filling?
What drug class is noradrenaline and vascular filling in?
What development phase is noradrenaline and vascular filling in?
What are the side effects of noradrenaline and vascular filling?
What does noradrenaline and vascular filling target?
Related
- Drug class: All Sympathomimetic drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor
- Manufacturer: Centre Hospitalier Universitaire, Amiens — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypotension
- Indication: Drugs for Anaphylactic shock
- Compare: noradrenaline and vascular filling vs similar drugs
- Pricing: noradrenaline and vascular filling cost, discount & access